Associated Papers
Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region.
Haars J et al.
Infectious Diseases (london, England), 2025
Select a paper to view details